Compare Globus Medical Inc. Class A Common Stock (GMED) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Jones Lang LaSalle Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Jones Lang LaSalle Inc trades at $294.36 (market cap $13.73B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Jones Lang LaSalle Inc for 71 Days on average.
| GMED | JLL | |
|---|---|---|
Market Cap | $10.25B | $13.73B |
Volume | 1,108,124 | 368,437 |
Sector | Health | Real Estate |
52-Week High | $96.82 | $392.79 |
52-Week Low | $58.33 | $280.16 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $9.76B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
JLL trades at $295.25, down 0.96% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $20.9B in 2022 to $26.1B in 2025, and improving net margins. Recent acquisitions and strategic appointments highlight operational momentum, while analyst consensus remains bullish with a $450.50 price target.
The outlook is positive given valuation discounts (P/E 14.31, P/S 0.52) and robust cash flow growth, though risks include real estate market cyclicality and technical resistance near $297. Upside hinges on continued execution and sector tailwinds, supporting a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
